CD274 and metastatic neoplasm: However, when the donation policy pricing for pembrolizumab was considered, enhanced cost-effectiveness was observed in several subgroups: patients under 65 years (3.22%), white race individuals (0.10%), those with ECOG scores of 0 (0.17%) or 1 (0.11%), PD-L1 CPS of 1 to less than 10 (0.21%) and 10 or above (16.20%), patients receiving concomitant bevacizumab (6.20%), and those without metastatic disease at diagnosis (15.78%).